Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Zentalis (ZNTL) to $4 from $8 and keeps an Equal Weight rating on the shares after the company reported Q3 earnings and highlighted progress with enrollment ongoing in the DENALI Part 2a study for azenosertib in platinum resistant ovarian cancer. The firm has fine tuned its azenosertib revenue estimates, having increased its PROC revenue estimate, removed revenues from non-gynecological indications and decreased its peak sales estimate to $511M from $867M previously.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC
- Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
- Zentalis reports Q3 EPS (37c), consensus (48c)
- Strategic Advancements and Promising Developments Drive Buy Rating for Zentalis Pharmaceuticals
- Zentalis board member Letai frontrunner to lead NCI, STAT reports